Psychological impact of screening for familial ovarian cancer: Reactions to initial assessment

Gynecologic Oncology

Volumn 65, Issue 2, 1997, Pages 197-205

  Robinson, Gail Erlick ^a   Rosen, Barry P ^a   Bradley, Linda N ^a   Rockert, Wendy G ^a   Carr, Melanie L ^a   Cole, David E C ^a   Murphy, K Joan ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANXIETY NEUROSIS; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SCREENING; DEPRESSION; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0031149974     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4686     Document Type: Article

References (34)

1. Cannistra S A. Medical progress: cancer of the ovary. N Engl J Med. 329:1993;1550-1559.
2. Narod S A, Madlensky L, Bradley L. Hereditary and familial ovarian cancer in Southern Ontario. Cancer. 74:1994;2341-2346.
3. Cole D EC, Gallinger S, McCready D R. Genetic counselling and testing for susceptibility to breast, ovarian and colon cancer: Where are we today? Can Med Assoc J. 154:1996;149-155.
4. Ford D, Easton D F, Bishop D T, Narod S A, Goldgan D E. The Breast Cancer Consortium: Risks of cancer in BRCA1 mutation carriers. Lancet. 343:1994;692-695.
5. Collins F S. BRCA1 - Lots of mutations, lots of dilemmas. N Engl J Med. 334:1996;186-188.
6. Foulkes W D, Narod S A. Hereditary breast and ovarian cancer: epidemiology, genetics, screening and predictive testing. Clin Invest Med. 18:1995;473-483.
7. Bourne T H, Campbell S, Reynolds K M. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. Br Med J. 306:1993;1025-1029.
8. Marteau T M. Psychology and screening: narrowing the gap between efficacy and effectiveness. Br J Clin Psychol. 33:1994;1-10.
9. Kaunitz A M. Oral contraceptives and gynaecologic cancer: an update for the 1990's. Am J Obstet Gynecol. 167:1992;1171-1176.
10. Tobacman J K, Greene M H, Tucker M A. Intra-abdominal carcinomatosis after prophylactic oophorectomy in cancer prone families. Lancet. 1982;795-797.
11. Wardle J, Pope R. The psychological costs of screening for cancer. J Psychosom Res. 36:1992;609-624.
12. Haynes B R, Sackett D L, Taylor W D. Increased absenteeism from work after detecting and labelling of hypertensive patients. N Eng J Med. 299:1978;741-744.
13. Bloom J R, Monterossa S. Hypertension labelling and sense of well-being. Am J Public Health. 71:1982;1226-1232.
14. Lynch H T, Watson P, Conway T A. DNA screening for breast/ovarian cancer susceptibility based on linked markers: a family study. Arch Intern Med. 53:1993;1979-1987.
15. Wardle F J, Collins W, Pernet A L. Psychological impact of screening for familial ovarian cancer. J Natl Cancer Inst. 85:1993;653-657.
16. Wardle J, Pernet A, Collins W. False positive results in ovarian cancer screening: one year follow-up of psychological status. Psychol Health. 10:1994;33-40.
17. Ellman R, Angeli N, Christians A. Psychiatric morbidity associated with screening for breast cancer. Br J Cancer. 60:1989;781-784.
18. Reelick N F, DE Haes W F, Schurman J H. Psychological side-effects of the mass screening on cervical cancer. Soc Sci Med. 18:1984;1089-1093.
19. Andolf E, Jorgensen C, Uddenberg N. Psychological effects of ultrasound screening for ovarian carcinoma. J Psychosom Obstet Gynaecol. 11:1990;155-162.
20. Stoate H. Can health screening damage your health? J R Coll Gen Pract. 39:1989;193-195.
21. Nance M A, Leroy B S, Orr H T. Protocol for genetic testing in Huntington disease: three years of experience in Minnesota. Am J Med Genet. 40:1991;518-522.
22. Benjamin C M, Adam S, Wiggins S. Proceed with care: direct predictive testing for Huntington Disease. Am J Hum Genet. 55:1994;606-617.
23. Lerman C, Daly M, Masny A. Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol. 12:1994;843-850.
24. Lerman C, Narod S, Schulman K. BRCAI testing in families with hereditary breast-ovarian cancer. JAMA. 275:1996;1885-1892.
25. Radloff L S. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measurement. 1:1977;385-401.
26. C, D, Spielberger, R, L, Gorsuch, R, Luchene, et al. State Trait Anxiety Inventory Form Y, Palo Alto, CA.
27. Botkin J R, Croyle R T, Smith K R. A model protocol for evaluating the behavioral and psychosocial effects of BRCAI testing. J Natl Cancer Inst. 88:1996;872-882.
28. Lerman C, Rimer B K, Engstrom P F. Cancer risk notification: psychosocial and ethical implications. J Clin Oncol. 9:1991;1275-1282.
29. Alagna S W, Morokoff P J, Bevett J M. Performance of breast self-examination with women at high risk for breast cancer. Woman Health. 12:1987;29-46.
30. Lerman C, Croyle R. Psychological issues in genetic testing for breast cancer susceptibility. Arch Intern Med. 154:1994;609-616.
31. Shaw R E, Cohen F, Doyle B. The impact of denial and repressive style on information gain and rehabilitation outcomes in myocardial infarction patients. Psychosom Med. 47:1985;262-273.
32. Irvine M J, Logan A G. Is knowing your cholesterol number harmful? J Clin Epidemiol. 47:1994;131-145.
33. Wertz D C, Sorenso J R, Heeren T C. Client's interpretation of risks provided in genetic counselling. Am J Hum Genet. 39:1986;253-264.
34. Garber C, Wang S J, Karlan B. Efficacy of genetic counselling in an ovarian cancer early detection program. Am J Hum Genet. 53:1993;A44.